Abstract
The number of people living with dementia worldwide is projected to reach 150 million by 2050, making prevention a crucial priority for health services1. The co-occurrence of two or more chronic health conditions, termed multimorbidity, occurs in up to 80% of dementia patients2, raising the potential of multimorbidity as an important risk factor for dementia. However, precise understanding of which specific conditions, as well as their age of onset, drive the link between multimorbidity and dementia is unclear. We defined the patterns of accumulation of 46 chronic conditions over their lifetime in 282,712 individuals from the UK Biobank. By grouping individuals based on their life-history of chronic illness, we show here that risk of incident dementia can be stratified by both the type and timing of their accumulated chronic conditions. We identified several distinct clusters of multimorbidity, and their associated risks varied in an age-specific manner. Compared to low multimorbidity, cardiometabolic and neurovascular conditions acquired before 55 years were most strongly associated with dementia. Acquisition of mental health and neurovascular conditions between the ages of 55 and 70 was associated with an over two-fold increase in dementia risk compared to low multimorbidity. The age-dependent role of multimorbidity in predicting dementia risk could be used for early stratification of individuals into high and low risk groups and inform targeted prevention strategies based on a person’s prior history of chronic disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Canadian Institutes of Health Research UK Medical Research Council Wellcome Trust UK Alzheimer's Society Academy of Medical Sciences HDH Wills 1965 Charitable Trust European Commission
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study received ethical approval from the Northwest Multi-Centre Research Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in this study are available from the UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). As restrictions apply to the availability of these data, which were used under licence for the current study, the authors cannot publicly share this data. The use of data from the UK Biobank was approved by the UK Biobank Access Committee (Project No. 95758). Code for this project is available at https://git.fmrib.ox.ac.uk/psp365/mm_risk.
